about
Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinomaNeurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population.Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup.The birth and rise of a craniopharyngioma: the radiological evolution of an incidental craniopharyngioma detected on serial MRI during medical treatment of a macroprolactinoma.Treating prolactinomas with dopamine agonists: always worth the gamble?The safety of treatments for prolactinomas.A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.Epidemiology and radiological geometric assessment of pituitary macroadenomas: population-based study.Giant prolactinomas: are they really different from ordinary macroprolactinomas?Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1.Ten-year follow-up of a giant prolactinoma.Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.The longest stalk: preserved pituitary function after regression of a giant prolactinoma.The therapeutic effect of bromocriptine in combination with spironolactone in patients with primary aldosteronism: a hypothesis generating pilot study.Long-term outcome of multimodal therapy for giant prolactinomas.Beat the giant: case of a giant prolactinoma during pregnancy on cabergolineGiant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome
P2860
Q34530133-6EB66A54-762C-4BEC-B8AE-33259A7F485AQ35197949-5DFA59D3-98B8-4F96-BF26-EAD261631340Q37480022-23ED798E-F5AE-4D88-ADD5-2B1903513B84Q37577813-5CD600EA-E137-431D-8A74-9DAFFF9C71CBQ38580100-D8A8B06E-402B-41D8-8566-EAA697848FFEQ38726058-FEDF0D4E-3972-4F59-BEBA-41512E8306ABQ38929926-4C0D1220-6D80-4E2C-A583-57982505FD14Q39902353-725E067E-4BD5-41F6-BC7A-543712E205C6Q40329835-52456B2F-471A-42C8-95ED-586CD1FEE2A3Q40730569-441D406E-F7C5-4DB0-B41C-2C8FA9532B9AQ44183655-EC6CE2D4-2899-4CBB-91E1-DAD9C3D37317Q44960679-56D2E26A-CB24-4624-8921-3D242B13D0CEQ45052960-A2B310CE-C1A5-45D0-8690-17F683BEB95BQ47148464-248D6F96-A3AD-4B34-8C53-B4969C9F550BQ47669109-39683456-776F-4954-8C49-20955AEB7F3EQ58713457-213D4CBB-7167-49BC-92BA-2BE99117AA27Q58780637-9D416043-8C3E-4B09-9C66-B83B44961C99
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Giant prolactinomas: the therapeutic approach.
@en
type
label
Giant prolactinomas: the therapeutic approach.
@en
prefLabel
Giant prolactinomas: the therapeutic approach.
@en
P2093
P2860
P356
P1476
Giant prolactinomas: the therapeutic approach
@en
P2093
Aline B Moraes
Cintia Marques dos Santos Silva
Mônica R Gadelha
P2860
P304
P356
10.1111/CEN.12242
P577
2013-06-11T00:00:00Z